Denis Chem Lab Limited has issued a formal response to the BSE regarding recent movements in its share price, clarifying that no undisclosed material information is driving the price changes. The pharmaceutical company, which specializes in manufacturing parenteral products, addressed the exchange's inquiry through a comprehensive disclosure dated April 10th, 2026.

Company's Official Response

In response to BSE's email reference L/SURV/ONL/PV/APJ/2026-2027/3585 dated April 9th, 2026, Denis Chem Lab Limited provided detailed clarification on the price movement concerns. The company emphasized its commitment to regulatory compliance and transparent disclosure practices.

Regulatory Compliance Statement

The company stated that all material information bearing on operations and performance, including price-sensitive information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been disclosed within stipulated timeframes. Denis Chem Lab Limited confirmed there is no pending information or announcements that could influence price behavior in the scrip.

Management's Position on Price Movement

The pharmaceutical manufacturer attributed the share price movements to market conditions, stating they are "purely due to market conditions and absolutely market driven." The management clarified that it has no connection with the price movements, emphasizing the market-driven nature of the fluctuations.

Company Background

Denis Chem Lab Limited operates as a manufacturer of parenteral products and holds ISO 9001:2008 certification. The company is incorporated under CIN L24230GJ1980PLC003843 and maintains its registered office in Ahmedabad, Gujarat. The response was digitally signed by Company Secretary and Compliance Officer Anal R. Desai, reinforcing the official nature of the clarification.

Denis chem lab Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI depositories regulations. The pharmaceutical manufacturer submitted the mandatory documentation for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited on April 6, 2026. The filing was signed by Anal Desai, Company Secretary and Compliance Officer of Denis Chem Lab Limited.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued the compliance certificate as the company's registrar and share transfer agent. The certificate was dated April 1, 2026, and signed by Ashok Shetty, Sr. Vice President-Corporate Registry.

The registrar confirmed that securities received from depository participants for dematerialization during the quarter were properly processed within prescribed timelines. All security certificates received for dematerialization were confirmed or rejected appropriately, with certificates being mutilated and cancelled after due verification.

Company Background

Denis Chem Lab Limited operates as a manufacturer of parenteral products in the pharmaceutical sector. The company is incorporated with CIN L24230GJ1980PLC003843 and maintains its registered office in Ahmedabad, Gujarat.

The quarterly filing demonstrates the company's adherence to SEBI regulations governing depositories and participants, ensuring proper handling of dematerialized securities and maintaining transparency with stock exchange authorities.